Giving attendees the means needed to mitigate risk and help projects run smoother is essential.
Horsham, PA (PRWEB) October 10, 2012
This meeting will spotlight challenges and offer solutions within health product lifecycles. Canada’s most forward-thinking leaders of government, industry, and patient advocacy, will participate in specific cross-functional sessions, best practices presentations, preconference tutorials, networking opportunities and table top exhibits, plus hearing valuable insight from speakers and patients.
Session topics include clinical trial design, EU legislation, managing drug shortages, risk communication methods, challenges facing industry regulators, electronic submission gateway project and managing risk in advertising, plus tutorials on new drug submissions and preparing for a pharmacovigilance regulatory inspection.
Opening Plenary Session on November 6, The Big Risks of Today; Forecasts for Tomorrow includes four of the region’s top industry leaders:
- Robert Cushman, MD, FRCPC, Director General, Biologics and Genetic Therapies, Directorate, Health Canada;
- Jeffrey Turnbull, CM, MD, MER, FRCPC, Chief of Staff, Ottawa Hospital, President, Canadian Medical Association;
- Christine Janus, Executive Director, Canadian Skin Patient Alliance;
- Neil Maresky, MD, Vice President, Scientific Affairs, AstraZeneca Canada, Inc.
“Giving attendees the means needed to mitigate risk and help projects run smoother is essential,” Track 3 Chair Robyn Lim, Ph.D., Senior Science Advisor, Office of Legislative and Regulatory Modernization, Health Products and Food Branch, Health Canada. “Additionally feedback from invited local patient participants with serious chronic conditions will enrich the discussions and provide valuable insights to improve the current methods as well raise awareness across the decision-making health community about the latest trends and progressing strategies in drug development and regulation.”
Register for DIA Canadian Annual Meeting 2012: Evolutions in Risk Thinking here.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. http://www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, Flickr and YouTube.
Stay updated on hot topic news at #druginfoassn on Twitter.